Future Science GroupBrowse
Supplemental figure 1.pdf (233.66 kB)
Download file

Supplementary Figure 1. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines

Download (233.66 kB)
figure
posted on 2021-05-14, 09:24 authored by Alessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, Sara Pilotto, Fabiana Cecere, Alessandro Follador, Valentina Polo, Alessandro Del Conte, Giulia Sartori, Marco Giavarra, Daniela Scattolin, Stefano Indraccolo, Stefano Frega, Giovanna De Maglio, Jessica Menis, Laura Bonanno, Fiorella Calabrese, Valentina Guarneri, PierFranco Conte, Giulia Pasello

Supplementary Figure 1. Real world data on treatment outcomes in EGFR mutant NSCLC patients receiving osimertinib in second or further lines

Survival curves for EGFR T790M mutation positive patients receiving osimertinib as second line treatment compared to further line treatment. A. Progression free survival (PFS). B. Overall survival (OS).

History

Usage metrics

Read the peer-reviewed publication

Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
Future OncologyFuture Oncology

Categories

Keywords

Non-small cell lung cancerEpidermal Growth Factor ReceptorTyrosine Kinase InhibitorsAcquired resistanceEGFR T790M mutationCancer Therapy (excl. Chemotherapy and Radiation Therapy)Molecular TargetsSolid Tumours

Licence

CC BY-NC-ND 4.0

Exports